The medical black technology system of the top student

Hemophilia, an X-linked congenital bleeding disorder, is caused by a single gene mutation leading to insufficient secretion or functional defect of coagulation factor VIII or coagulation factor IX.

Because there is only one X chromosome in male genes, this recessive genetic disease will be manifested genetically.

However, women have two X chromosomes in their genes, and most of this genetic disease is recessive.

But in a few cases, it will still show up.

Among them, Queen Victoria is the most famous carrier of hemophilia. Because of her, the entire royal family's genes were damaged. In addition, due to incest marriages in the royal family, hemophilia was frequent among the royal family members at that time.

Lu Liang briefly checked the research related to hemophilia on the Internet.

The pathogenesis of hemophilia seems simple, but in fact it is anything but simple.

Ultimately, hemophilia involves genes.

As we all know, anything that has anything to do with genes is definitely not simple!

Moreover, one or two things can be seen from the current treatment methods.

Even with the development of science and technology, the mainstream treatment methods for hemophilia can still only use the traditional method of making up for what is missing.

If the coagulation factor VIII is lacking, the coagulation factor VIII will be supplemented. If the coagulation factor IX is lacking, the coagulation factor IX will be supplemented.

Lu Liang took a deep breath. He estimated that the analysis of the drug this time would not go well.

As his thoughts moved, the system interface appeared in front of him.

[Level: lv3]

[Analysis object: human coagulation factor VIII]

[A coagulation factor extracted from plasma, which has a corrective effect on coagulation disorders caused by the lack of human coagulation factor VIII. 】

[Source points required for analysis: 5]

[Existing source point: 5.6]

[Analysis: A drug for treating hemophilia is available. 】

[Start parsing? 】

After seeing the number of source points required for analysis, Lu Liang couldn't help but grin.

He knew that this matter was not that simple.

5 source points, this time the analysis required more source points than he imagined.

Lu Liang initially felt that the 4.2 source points brought to him by the sales of metformin would be enough for him to use for a long time.

But now it seems that these sources still seem to be stretched thin.

One analysis was enough to wipe out his entire family fortune.

Is it because what was analyzed this time was a drug targeting genes?

However, Lu Liang didn't think too much and directly chose to analyze.

There was a bang sound, as if something exploded in my mind.

Knowledge about drug preparation processes rushed into Lu Liang's mind like a river bursting its banks.

Antigens, B lymphocytes, hybridoma technology, genetic engineering technology.

After seeing the final product in the drug preparation roadmap, Lu Liang's pupils couldn't help but shrink.

It is a product of the immunoglobulin IgG structural pattern.

What was analyzed this time turned out to be a monoclonal antibody drug!

What are monoclonal antibodies?

The full name of monoclonal antibody is monoclonal antibody!

In 1975, molecular biologists G.J.F. Koehler and C. Milstein, based on natural hybridization, fused mouse myeloma cells with pure-line mouse B cells that had been immunized with antigens to prepare a cell line. hybridoma cells.

This hybridoma cell not only has the characteristics of tumor cells that proliferate indefinitely in the body, but also has the characteristics of secreting and synthesizing specific antibodies.

When this hybridoma is cultured as a single cell, a single cell line, that is, a single clone can be formed.

Specific antibodies prepared using this cell population are monoclonal antibodies.

As long as there are no mutations during the inoculation and culture process, the structure, amino acid sequence, specificity, etc. of this antibody will be consistent!

Completely different from the previous chemically synthesized drugs, this is a biopharmaceutical!

Since the advent of monoclonal antibodies, their unique characteristics have been rapidly used in many fields such as cancer and immune system diseases. Monoclonal antibody drugs have become the most important category of biopharmaceuticals.

G.J.F. Koehler and C. Milstein won the 1984 Nobel Prize in Medicine for their monoclonal antibodies.

What Lu Liang analyzed this time was exactly a kind of micizumab.

Unlike ordinary monoclonal antibodies, emicizumab is a humanized IgG4 bispecific antibody.

The structure of ordinary monoclonal antibody drugs is symmetrical, and the Fab segment antigen-binding site is the same.

However, the left and right structures of Imicizumab are not asymmetrical, and the two Fab variable regions have different antigen-binding sites.

To use a less vivid metaphor, an ordinary monoclonal antibody is equivalent to a Yan Shuangying with two pistols, and Aimedizumab is equivalent to a Yan Shuangying holding a Gatling and shoulder-resistant RPG.

It can be described as terrifying.

The therapeutic mechanism of emicizumab for hemophilia is even simpler.

The cause of hemophilia is congenital inheritance and a lack of key coagulation factor VIII in the body.

As a result, coagulation factor IX cannot bind to coagulation factor X, causing coagulation dysfunction.

The role of Imicizumab is to replace the key coagulation factor VIII, bridging the coagulation factor IX and the coagulation factor X, allowing the coagulation process to bypass the key coagulation factor VIII.

If you don’t have coagulation factor Ⅷ, then don’t use it, we will still coagulate your blood!

Perhaps the name Imicizumab is a bit confusing, but it has another familiar name.

Shuyoulile!

Lu Liang quickly recorded the preparation process of Shuyoulile on paper.

Compared with chemically synthesized drugs, the bioprocessing and technology of monoclonal antibody drugs are more complex, involving processes such as molecular structure and function research, cell line development and downstream purification.

Small changes in the structure of the monoclonal antibody drug and the type and content of impurities in the drug may have a significant impact on product safety and effectiveness.

While recording the preparation process of the monoclonal antibody, Lu Liang conveniently wrote the drug patent application for Sulfuret.

He is now more familiar with the process of patent application, so writing a patent application is particularly confusing.

After completing the writing of the drug patent application, Lu Liang checked it carefully to confirm that there were no problems, and submitted the drug patent application online.

Now that the patent is complete, there is only one last thing left.

That is to produce a small batch of drug samples for testing.

Lu Liang took out his mobile phone. Before he produced metformin drug samples, he always approached Wang Donglai directly, and Wang Donglai helped produce drug samples in the factory.

But the situation is different now. After the contract with Wang Donglai is terminated, it is naturally impossible to go to Wang Donglai again to prepare drug samples.

Matters in this area naturally have to be handled by the person in charge of the new factory.

Lu Liang knew the person in charge of the new factory. He had met him when they signed the contract. He was a middle-aged man with glasses and a serious expression. The two of them had also left each other's contact information.

Lu Liang found the contact information of a person named Tian Li from the address book, and then dialed the number.